Latest Commercialization News

Althea Group Holdings reported a resilient September quarter with $5.4 million in receipts despite a major strike in British Columbia, bolstered by a $2.53 million capital raise and expansion in the US THC beverage market.

Eden Innovations reports solid Q1 FY2026 sales growth with expanding EdenCrete® and OptiBlend® markets, alongside key US property sale developments aimed at debt reduction.

Firebrick Pharma is set to expand its Nasodine product line with the launch of a new throat spray, targeting export markets starting November 2025, beginning with Singapore.

Anax Metals has made significant progress on its Whim Creek Copper-Zinc project, securing a waste rock processing agreement and continuing efforts to finalize project financing.

Cazaly Resources reports strong gold assay results at its Goongarrie Gold Project, confirming mineralisation over a 700m strike and prompting an expanded aircore drilling program. The company maintains a solid cash position of $2.4 million as it advances multiple exploration fronts.

Horseshoe Metals reports encouraging RC drilling results at its Horseshoe Lights Copper-Gold Project, confirming wide zones of near-surface oxide copper mineralisation at Motters. The company is advancing towards Direct Shipping Ore operations and progressing offtake negotiations.

CONNEQT Health reports robust 50% quarter-on-quarter growth in Pulse device sales and launches a new pricing strategy to boost recurring revenue. The company also secures a significant US clinical trial contract and advances cost-cutting efforts.

Cleo Diagnostics has successfully completed Stage 1 of the Medical Device Single Audit Program, marking a significant step toward FDA submission and global commercialisation of its ovarian cancer test.

Lithium Universe Limited has secured exclusive rights to a breakthrough silver extraction technology from Macquarie University, promising high-purity silver recovery from solar panels while preserving valuable silicon wafers. This innovation complements their existing recycling and lithium refining strategies in North America.

OncoSil Medical reports a remarkable 917% increase in quarterly cash receipts alongside promising clinical trial results and key European market entries, signaling robust momentum in its pancreatic cancer treatment rollout.

Paradigm Biopharmaceuticals has initiated dosing in its pivotal Phase 3 trial for knee osteoarthritis pain, backed by a strong cash position and strategic portfolio expansion. The company targets accelerated recruitment and a mid-2026 interim analysis.

Terragen Holdings expands its probiotic product range into beef and lamb feedlots, secures key international approvals, and progresses large-scale trials while maintaining a $3 million cash reserve.